Gsk Share Discussion Threads

[tim 3] 19/12/2016 09:59

Broker rec price targets follow rather than lead in my experience.

[essentialinvestor] 19/12/2016 09:38

Another Phase 111 study underway.

Broker recs as good as meaningless imv, they can alter price targets in the
blink of an eye.

2017 a big year for GSK with a new CEO and possible clarifaction of strategy
going forward, would expect another cost cutting programme to be initiated.

[ny boy] 19/12/2016 09:31

0n hl.co.uk web site broker recs.. shows 8 out of 15 as a strong buy

Chart resistance at 1715p

[philanderer] 19/12/2016 09:20

19th dec Jefferies buy tp 1700p cut from 1850p

[linton5] 19/12/2016 09:10

I agree ny

[ny boy] 19/12/2016 09:01

I have been buying this morning, support 1510p, looking for a move to 1700p+ next year and the divi is over 5%! ffs!

[essentialinvestor] 16/12/2016 13:55

More positive news for ViiV, would hope that is a limited demographic.

[essentialinvestor] 16/12/2016 08:54

Could have been this time next week, so hopefully out of the way before the 25th.

[essentialinvestor] 16/12/2016 08:19

On the Beechams Max Strenght today, at least the share price looks a little
better atm.

[philanderer] 15/12/2016 17:23

GlaxoSmithKline plc’s (ADR) (NYSE:GSK) Opens Its First Fully Dedicated Vaccines R&D Center In Rockville

[essentialinvestor] 15/12/2016 09:08

Approx 18x on the forecasts I use, however there are so many bloody ways
of calculating EPS now, core, non core etc.

[thewheeliedealer] 15/12/2016 01:36

Hi all,

I bought some more GSK via a Spreadbet this morning and I scribbled a quick Blog on my Website about why I made my move with really a big focus on the Technicals and I have included a few charts. I hope it helps,

regards, WD

[essentialinvestor] 14/12/2016 12:42

M, approx 75% of prescribed drugs in the US are now generic.
Innovation can still underpin profitability as with the GSK and ViiV.

Tens of thousands are still dying of cancer, we have huge scope for
future treatments in AD(hopefully). Superbugs now estimated to kill more
people in the UK yearly than breast cancer, GSK one of the few major pharmas left in antibiotic research.

Undoubtedly sector headwinds,
cost/benefit coupled with innovation is the key imv.

[mj19] 14/12/2016 12:27

HSBC reiterated Glaxosmithkline (LON:GSK) as 'Buy' With 1970 PTBy Warren Smith / in UK Broker Ratings / on Wednesday, 14 Dec 2016 11:40 AM / 0 CommentsAccording to a report issued to investors by HSBC on Tuesday, shares of Glaxosmithkline (LON:GSK) had their rating reiterated by analysts to 'Buy'.The analyst stated that the investment firm has set a price target of 1970 on shares of LON:GSK. Based on the brokers price target of 1970, this means HSBC believes there is a potential increase of 32.79% from the current stock price of 1483.5.

[philanderer] 13/12/2016 23:31

12/13/2016

LONDON (Alliance News) - Pharmaceuticals group GlaxoSmithKline PLC on Tuesday said it has submitted a regulatory application in Japan for its Belimumab drug to treat lupus.

[minerve] 13/12/2016 23:22

With the uptake in Obama care I would have thought the increase of the % of population who now have access to treatment and medication may potentially offset the pressure on pricing. Equally an improvement in the economy will generally help sales because more employees with be covered under employer schemes and 'discretionary' sales - where the patient part pays for drugs or to see a physician - will improve due to rising incomes. Many in the past who didn't have the money and/or employment would simply have taken 'drug holidays' or simply missed diagnosis and treatment altogether.

[essentialinvestor] 13/12/2016 22:59

AW gave an interview to CNBC discussing their US vaccine investment,
also made some comments on US drugs pricing, mainly a reiteration of
previous views coupled with how GSK is pricing new medications in the US market.

With both the UKX and defensives strong today would expect share price support,
a gain against wider trend usually more interesting imv.

[philanderer] 13/12/2016 17:10

Fingers crossed :-)


GlaxoSmithKline’s New R&D Center to House 450 Scientists and Support Staff, Will Create Up to 200 New Jobs

[woodhawk] 13/12/2016 16:19

Recovery under way now?

[philo124] 13/12/2016 13:40

Great , thanks.

[mj19] 13/12/2016 13:34

Rating Worth Watching: Glaxosmithkline (LON:GSK) Stock Buy Rating Reiterated at HSBC; The Target Price Given is GBX 1970.00December 13, 2016 - By Linda RogersGlaxosmithkline (LON:GSK) RatingHSBC currently has a GBX 1970.00 PT on the 72.22B GBP market cap company or 32.75% upside potential. In a note revealed to clients and investors on 13 December, Glaxosmithkline (LON:GSK) stock had its Buy Rating reiterated by equity analysts at HSBC.

[mj19] 12/12/2016 17:32

Dividend Darling With Solid Upside? Analysts Put This Stock on Investor's Radar: GlaxoSmithKline plc (NYSE:GSK)December 12, 2016 CSZ Staff If investors are looking for a stable dividend stock with upside, GlaxoSmithKline plc (NYSE:GSK) could be one that fits the bill. The stock currently provides a dividend yield of 4.92% for the Healthcare company. Sell-side analysts covering the shares are projecting that it will reach $48.25 within the next 12-18 months. This is a solid upside to a recent tick of $37.79. On a consensus basis, analysts have a Buy/Sell rating of 2.00, which is based on a 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell. A dividend is used when a company's board of directors issue a portion of the company's earnings to its shareholders. These dividends can be in the form of a cash payout, as stock shares, or as other property. The dividend rate can be quoted as a percent of the current market price, known as the dividend yield, or quoted in terms of the dollar amount each share gets, called dividends per share or DPS.Profits of a company can be distributed to their shareholders by a dividend, or can be kept as retained earnings within the company. The company might choose to use their net profits and buy back their own shares out in the markets as a share buyback. Dividends and share buy-backs don't change the value of a company's shares. Dividend payments are approved by shareholders and could be structured as a one-time dividend, or as a cash flow to investors and owners.High-growth companies such start-ups like those in the technology or biotechnology sectors usually don't offer dividends because they need to use all of their profits reinvested back into the company in order to sustain the higher-than-average growth that they need. More established companies will issue regular dividends because they want to maximize shareholder wealth. Companies in the sectors of oil and gas, basic materials, healthcare and pharmaceuticals, banks and financial, utilities, and REITS tend to issue dividends more than other sectors.